Research programme: antileukotriene monoclonal antibodies - Lpath

Drug Profile

Research programme: antileukotriene monoclonal antibodies - Lpath

Alternative Names: Altepan™; Anti-leukotriene antibody - Lpath; Leukotriene inhibitors - Lpath

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lpath
  • Class Monoclonal antibodies
  • Mechanism of Action Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Inflammatory bowel diseases

Highest Development Phases

  • Preclinical Inflammation; Inflammatory bowel diseases
  • No development reported Asthma; Respiratory tract disorders

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for preclinical development in Asthma in USA (Parenteral)
  • 28 Dec 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (Parenteral)
  • 28 Jul 2015 Preclinical trials in Inflammatory bowel disease in USA (Parenteral) prior to July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top